Four-year follow-up data of the ELOQUENT-2 trial (ClinicalTrials.gov: NCT01239797) demonstrated that elotuzumab plus lenalidomide/dexamethasone (ELd) has ongoing efficacy among patients with relapsed/refractory multiple myeloma, according to a press release.1
The data showed that patients receiving the combination maintained a reduction of risk of disease progression or death of 29% (hazard ratio [HR], 0.71; 95% CI: 0.59-0.86).
ELd therapy continued to show clinical benefit and a sustained relative improvement of 50% in progression free survival (PFS) of 21% vs 14% for patients who received lenalidomide/dexamethasone (Ld) alone.
Patients treated with ELd had a doubled median PFS compared with Ld alone (15.2 vs 7.4 months, respectively).
Patients who received ELd had an overall response rate (ORR) of 79% compared with 66% of patients who received Ld.
An overall survival (OS) benefit was observed in patients receiving ELd of 48 months vs 40 months with Ld.
The rates of adverse effects (AE) remained consistent with findings reported at previous follow-ups. The most commonly reported AEs included diarrhea, fatigue, anemia, pyrexia, constipation, neutropenia, cough, back pain, and muscle spasms.
- Four-year follow-up with empliciti (elotuzumab) plus lenalidomide/dexamethasone (ELd) in patients with advanced multiple myeloma shows long-term efficacy in ELOQUENT-2 trial [news release]. Princeton, NJ: Bristol-Meyers Squibb; June 24, 2017. https://news.bms.com/press-release/corporatefinancial-news/four-year-follow-empliciti-elotuzumab-plus-lenalidomidedexamet. Accessed June 26, 2017.